148 related articles for article (PubMed ID: 29367611)
1. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.
Gao B; Lu Y; Nieuweboer AJM; Xu H; Beesley J; Boere I; de Graan AM; de Bruijn P; Gurney H; J Kennedy C; Chiew YE; Johnatty SE; Beale P; Harrison M; Luccarini C; Conroy D; Mathijssen RHJ; R Harnett P; Balleine RL; Chenevix-Trench G; Macgregor S; de Fazio A
Sci Rep; 2018 Jan; 8(1):1508. PubMed ID: 29367611
[TBL] [Abstract][Full Text] [Related]
2. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.
Huang RS; Johnatty SE; Gamazon ER; Im HK; Ziliak D; Duan S; Zhang W; Kistner EO; Chen P; Beesley J; Mi S; O'Donnell PH; Fraiman YS; Das S; Cox NJ; Lu Y; Macgregor S; Goode EL; Vierkant RA; Fridley BL; Hogdall E; Kjaer SK; Jensen A; Moysich KB; Grasela M; Odunsi K; Brown R; Paul J; Lambrechts D; Despierre E; Vergote I; Gross J; Karlan BY; Defazio A; Chenevix-Trench G; ; Dolan ME
Clin Cancer Res; 2011 Aug; 17(16):5490-500. PubMed ID: 21705454
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Sato Y; Yamamoto N; Kunitoh H; Ohe Y; Minami H; Laird NM; Katori N; Saito Y; Ohnami S; Sakamoto H; Sawada J; Saijo N; Yoshida T; Tamura T
J Thorac Oncol; 2011 Jan; 6(1):132-8. PubMed ID: 21079520
[TBL] [Abstract][Full Text] [Related]
4. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
5. Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents.
Chawla D; Kar R; Gupta B; Halder S; Garg S; Mehndiratta M; Wadhwa N; Agarwal R
Int J Gynecol Cancer; 2018 Jul; 28(6):1239-1246. PubMed ID: 29727353
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE; Beesley J; Paul J; Fereday S; Spurdle AB; Webb PM; Byth K; Marsh S; McLeod H; ; Harnett PR; Brown R; DeFazio A; Chenevix-Trench G
Clin Cancer Res; 2008 Sep; 14(17):5594-601. PubMed ID: 18765553
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
Dizon DS; Hensley ML; Poynor EA; Sabbatini P; Aghajanian C; Hummer A; Venkatraman E; Spriggs DR
J Clin Oncol; 2002 Mar; 20(5):1238-47. PubMed ID: 11870166
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
13. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts.
Tourell MC; Shokoohmand A; Landgraf M; Holzapfel NP; Poh PS; Loessner D; Momot KI
Sci Rep; 2017 Feb; 7():42905. PubMed ID: 28220831
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
